Recurrence and change in severity of intolerance AEs from prior ibrutinib or acalabrutinib exposure during zanubrutinib treatment in patients with CLL/SLL. ∗No intolerance AEs recurred at a higher grade. AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase.